<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31506" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Amiloride</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Almajid</surname>
            <given-names>Ali N.</given-names>
          </name>
          <aff>Imam Abdulrahman Bin Faisal University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassagnol</surname>
            <given-names>Manouchkathe</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ali Almajid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31506.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This activity centers on amiloride, a medication integral to the management of hypertension and heart failure. As a potassium-sparing diuretic, amiloride's indications, contraindications, and adverse drug reactions are discussed.&#x000a0;Additionally, amiloride's&#x000a0;FDA-issued box warning concerning hyperkalemia, pertinent drug interactions, mechanism of action, pharmacokinetics, and considerations in medical toxicology are also discussed. A&#x000a0;thorough understanding of amiloride's therapeutic employment is crucial for healthcare professionals to optimize cardiovascular patient care. The course imparts comprehensive insights into the complexities of administration and underscores the significance of diligent monitoring strategies. Effective navigation of amiloride therapy requires collaborative efforts among healthcare teams, emphasizing the imperative role of interprofessional cooperation in enhancing patient outcomes within cardiovascular care standards.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of amiloride.</p></list-item><list-item><p>Evaluate the adverse drug reaction associated with amiloride.</p></list-item><list-item><p>Implement&#x000a0;appropriate monitoring of patients taking amiloride to prevent potential toxicity.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from amiloride therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31506&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31506">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31506.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Amiloride is a potassium-sparing diuretic with a moderate diuretic effect compared to its potassium-sparing activity. Amiloride is a pyrazinoylguanidine derivative.<xref ref-type="bibr" rid="article-31506.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Amiloride is FDA-approved to be used adjunctively with thiazides (or other kaliuretic agents) for the treatment of chronic heart failure or uncomplicated essential hypertension to help restore normal serum potassium concentrations in those who develop hypokalemia on kaliuretic therapy. Amiloride is also indicated to prevent the development of hypokalemia in patients with a higher risk of hypokalemia (patients on digoxin therapy or patients with significant cardiac arrhythmias).<xref ref-type="bibr" rid="article-31506.r2">[2]</xref><xref ref-type="bibr" rid="article-31506.r3">[3]</xref><xref ref-type="bibr" rid="article-31506.r4">[4]</xref>&#x000a0;The American Heart Association/American College of Cardiology (AHA/ACC) guidelines state that amiloride is not the preferred medication for the initial management of hypertension. Amiloride can be combined with thiazide in cases of hypokalemia during thiazide monotherapy.<xref ref-type="bibr" rid="article-31506.r5">[5]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>The American Association for the Study of Liver Diseases endorses amiloride for refractory ascites.<xref ref-type="bibr" rid="article-31506.r6">[6]</xref>&#x000a0;As per guidelines by KDIGO (Kidney Disease: Improving Global Outcomes), amiloride&#x000a0;can be a helpful add-on therapy for nephrotic syndrome.<xref ref-type="bibr" rid="article-31506.r7">[7]</xref>&#x000a0;Amiloride might also be useful in thiazolidinediones-induced edema and lithium-induced polyuria.<xref ref-type="bibr" rid="article-31506.r8">[8]</xref><xref ref-type="bibr" rid="article-31506.r9">[9]</xref>&#x000a0;As an epithelial sodium channel blocker, amiloride has been researched in cystic fibrosis due to its ability to inhibit epithelial sodium channels (ENaC), potentially hydrating airway surfaces by reducing sodium absorption. Inhaled amiloride with tobramycin has been investigated to eradicate&#x000a0;<italic toggle="yes">Burkholderia cepacia</italic>&#x000a0;complex in patients with cystic fibrosis.<xref ref-type="bibr" rid="article-31506.r10">[10]</xref><xref ref-type="bibr" rid="article-31506.r11">[11]</xref>&#x000a0;The case report also describes amiloride for the treatment of severe refractory symptomatic hypokalemia associated with type 1 renal tubular acidosis.<xref ref-type="bibr" rid="article-31506.r12">[12]</xref>&#x000a0;Preclinical studies suggest that amiloride&#x000a0;can&#x000a0;induce apoptosis in multiple myeloma cell lines.<xref ref-type="bibr" rid="article-31506.r13">[13]</xref>&#x000a0;Amiloride's inhibition of ENaC and a low-sodium diet contribute to normalizing blood pressure and electrolyte levels in Liddle syndrome.<xref ref-type="bibr" rid="article-31506.r14">[14]</xref>&#x000a0;It is necessary to perform randomized controlled trials to validate these findings.</p>
      </sec>
      <sec id="article-31506.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Amiloride works by inhibiting the epithelial sodium channels (ENaC) in the distal nephron (distal convoluted tubule and cortical collecting duct), lung, and colon. These ENaCs are composed of&#x000a0;2 domains that span the apical membrane. Those domains are denoted M1 and M2. Intracellularly, there are C and N termini, while extracellularly, there is a large loop that contains 2 or 3 cysteine-rich domains. ENaCs have&#x000a0;3 subunits: &#x003b1;, &#x003b2;, and &#x003b3;.<xref ref-type="bibr" rid="article-31506.r15">[15]</xref>&#x000a0;Mutation in &#x003b2; or &#x003b3; subunits occurs in Liddle syndrome, where basal ENaCs activity increases. Amiloride is beneficial in Liddle syndrome, as described above.<xref ref-type="bibr" rid="article-31506.r16">[16]</xref></p>
        <p>Usually, sodium moves down its electrochemical gradient to enter the tubular cells through the ENaCs. This gradient results from the basolateral membrane Na/K ATPase. Reabsorption of Na is associated with depolarization of the apical membrane, which creates a lumen-negative transepithelial potential difference. The difference in electric potential enhances potassium secretion through the apical channels, increasing potassium excretion. Amiloride selectively inhibits ENaCs, decreasing hyperpolarization of the apical membrane and consequently decreasing potassium, hydrogen, calcium, and magnesium secretion. Because amiloride inhibits ENaCs, it can also lead to mild natriuresis.<xref ref-type="bibr" rid="article-31506.r17">[17]</xref><xref ref-type="bibr" rid="article-31506.r18">[18]</xref> Amiloride also has the potential to cause vasodilation.<xref ref-type="bibr" rid="article-31506.r19">[19]</xref>&#x000a0;Prolonged use of amiloride can reduce the excretion of renal uric acid by causing volume contraction and reabsorption of uric acid from the proximal convoluted tubule.</p>
        <p>The loop diuretics and thiazides will increase Na concentration in the distal convoluted tubule and cortical collecting duct. This increase in Na concentration couples with increased Na reabsorption and potassium secretion and excretion. Therefore, co-administration of amiloride with thiazide or loop diuretics decreases their kaliuretic effect and augments their antihypertensive and diuretic effect.</p>
        <p>Amiloride helps treat&#x000a0;insulin-induced edema. In this condition, ENaCs are upregulated, resulting in increased Na reabsorption and potassium secretion and excretion. However, amiloride is not that effective in hyperaldosteronism when compared to spironolactone and eplerenone.<xref ref-type="bibr" rid="article-31506.r20">[20]</xref>&#x000a0;Amiloride can induce apoptosis in multiple myeloma cell lines in mice, and therefore, it might be used to treat relapsed multiple myeloma in the future. The combination of amiloride with melphalan, lenalidomide, and dexamethasone showed a synergistic effect.<xref ref-type="bibr" rid="article-31506.r13">[13]</xref></p>
        <p>
<bold>Pharmacokinetics&#x000a0;</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Amiloride demonstrates an onset of action of 2 hours upon oral administration, with peak plasma concentrations attained within 3 to 4 hours. The effects of amiloride as a diuretic last for approximately 24 hours.</p>
        <p><bold>Distribution:</bold>&#x000a0;It exhibits extravascular distribution and a high volume of distribution (350 to 380 L) due to its small molecular weight and low plasma protein binding (&#x0003c;40%).<xref ref-type="bibr" rid="article-31506.r21">[21]</xref><xref ref-type="bibr" rid="article-31506.r22">[22]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;Amiloride is excreted unchanged by the kidneys and is not metabolized by the liver. Hence, drug accumulation is not expected in patients with liver dysfunction.</p>
        <p><bold>Elimination:</bold>&#x000a0;Around 50% of amiloride is excreted unchanged by the kidneys in urine, while approximately 40% is excreted via feces. In individuals with normal kidney function, amiloride has a serum half-life of 6 to 9 hours.<xref ref-type="bibr" rid="article-31506.r3">[3]</xref></p>
      </sec>
      <sec id="article-31506.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Amiloride is available as an oral tablet with a standardized strength of 5 mg. Amiloride is also available in combination with hydrochlorothiazide.<xref ref-type="bibr" rid="article-31506.r23">[23]</xref></p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>Congestive heart failure: 5 to 10 mg by mouth once daily or in divided doses. When managing congestive heart failure and achieving initial diuresis, the potassium loss might diminish, prompting a reassessment of the necessity for amiloride. Dosage adjustments may be required, and the continuation of therapy might be intermittent for maintenance purposes.</p>
        <p>Hypertension: 5 mg by mouth once daily. The dosage of amiloride may be increased to 10 mg/d if necessary. As per AHA/ACC guidelines, If hypokalemia is present, primary or secondary aldosteronism should be excluded; after careful evaluation, a potassium-sparing diuretic like amiloride can be considered.<xref ref-type="bibr" rid="article-31506.r5">[5]</xref></p>
        <p>Thiazide-induced hypokalemia: 5 to 10 mg orally once daily or in divided doses.<xref ref-type="bibr" rid="article-31506.r3">[3]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;The product label does not provide information on dose adjustment in case of hepatic impairment.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>The dosage needs to be adjusted in patients with renal impairment and contraindicated in severe renal impairment. AHA/ACC guidelines recommend avoiding amiloride if GFR &#x0003c;45 mL/min.<xref ref-type="bibr" rid="article-31506.r5">[5]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Amiloride is acceptable during pregnancy since it is FDA pregnancy category B.<xref ref-type="bibr" rid="article-31506.r24">[24]</xref>&#x000a0;The American College of Obstetricians and Gynecologists recommends the use of labetalol or nifedipine for the treatment of gestational hypertension.<xref ref-type="bibr" rid="article-31506.r25">[25]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;No information is available in the case of breastfeeding, so it is recommended to use alternative medicine.<xref ref-type="bibr" rid="article-31506.r26">[26]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;According to the FDA label, amiloride has not been established as safe and effective for pediatric patients. It is used off-label for the management of pediatric hypertension.<xref ref-type="bibr" rid="article-31506.r27">[27]</xref>&#x000a0;Amiloride is also used off-label in pediatric patients with nephrogenic diabetes insipidus.<xref ref-type="bibr" rid="article-31506.r28">[28]</xref>)</p>
        <p><bold>Older patients:&#x000a0;</bold>It should be used cautiously in patients with diabetes and patients 65 and older.<xref ref-type="bibr" rid="article-31506.r29">[29]</xref>&#x000a0;As per the American Geriatric Society's 2023 guidelines (Beers criteria), it is advised to refrain from utilizing amiloride in individuals older than 65 with a creatinine clearance of less than 30 mL/min due to the elevated risk of hyperkalemia and hyponatremia.<xref ref-type="bibr" rid="article-31506.r30">[30]</xref></p>
      </sec>
      <sec id="article-31506.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Amiloride is generally well tolerated, with few significant adverse effects other than the risk of hyperkalemia. The most common adverse drug reactions of amiloride include nausea, vomiting, diarrhea, and headache.<xref ref-type="bibr" rid="article-31506.r3">[3]</xref><xref ref-type="bibr" rid="article-31506.r31">[31]</xref>&#x000a0;Other adverse drug reactions are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Central nervous system: fatigue and dizziness</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Musculoskeletal system: muscle cramps and weakness</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal system: nausea, vomiting, diarrhea/constipation, abdominal pain, and anorexia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Respiratory: dyspnea and cough</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Genitourinary: impotence</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Endocrine and metabolic: glucose intolerance, hyperuricemia, hyperchloremic metabolic acidosis, hyperkalemia, and hyponatremia&#x000a0;<xref ref-type="bibr" rid="article-31506.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Simultaneous administration of a non-steroidal anti-inflammatory drug (NSAID) and amiloride can reduce the diuretic and antihypertensive effects of the amiloride. Hence, it is crucial to observe patients when amiloride and NSAIDs are used together to ensure that the desired diuretic effect is achieved. Additionally, monitoring the potassium and renal function is essential since administering amiloride and NSAID may increase serum potassium levels.<xref ref-type="bibr" rid="article-31506.r23">[23]</xref></p>
        <p>It is recommended to avoid concomitant use of drugs that blunt the renin-angiotensin-aldosterone system (angiotensin-converting enzyme inhibitors, beta-blockers, and aliskiren).<xref ref-type="bibr" rid="article-31506.r32">[32]</xref><xref ref-type="bibr" rid="article-31506.r33">[33]</xref></p>
        <p>Amiloride is contraindicated with other potassium-sparing diuretics such as&#x000a0;potassium-sparing diuretics (spironolactone or triamterene).&#x000a0;Amiloride and cyclosporine both increase serum potassium; coadministration is not recommended.<xref ref-type="bibr" rid="article-31506.r34">[34]</xref></p>
      </sec>
      <sec id="article-31506.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Amiloride can cause fatal hyperkalemia in susceptible patients. Amiloride is contraindicated if serum potassium levels are (&#x0003e;5.5 mEq/L).<xref ref-type="bibr" rid="article-31506.r35">[35]</xref>&#x000a0;Amiloride is contraindicated in acute or chronic renal insufficiency (serum creatinine &#x0003e;1.5 mg/dL or [BUN] &#x0003e;30 mg/dL), anuria, with concomitant use of other potassium-sparing diuretics (spironolactone or triamterene). Amiloride is contraindicated in documented hypersensitivity to amiloride or excipients.<xref ref-type="bibr" rid="article-31506.r36">[36]</xref><xref ref-type="bibr" rid="article-31506.r37">[37]</xref><xref ref-type="bibr" rid="article-31506.r38">[38]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Amiloride has an FDA-box warning for hyperkalemia, either alone or even when combined with hydrochlorothiazide.&#x000a0;Hyperkalemia might be fatal, especially in people with diabetes mellitus, older patients, and patients with renal impairment. Hyperkalemia tends to occur in patients who do not receive a concomitant kaliuretic diuretic. When amiloride is used concomitantly with thiazides, the risk of hyperkalemia drops below 2%. Amiloride should be used cautiously, and serum potassium levels should be carefully monitored in patients, especially during initiation, diuretic dosage adjustments, and any illness that could affect renal function.<xref ref-type="bibr" rid="article-31506.r39">[39]</xref></p>
      </sec>
      <sec id="article-31506.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Amiloride requires monitoring for hyperkalemia and impaired renal function.<xref ref-type="bibr" rid="article-31506.r24">[24]</xref> Therefore, periodic monitoring of serum potassium, BUN, and creatinine concentrations is essential. The parameters that also require monitoring are blood pressure, daily weight, serum bicarbonate, serum magnesium concentrations, and signs or symptoms of hyperkalemia.</p>
      </sec>
      <sec id="article-31506.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The most toxic effect of amiloride is hyperkalemia. A rapid increase in the extracellular potassium leads to an increase in cardiac conduction velocity, which lowers the threshold for rapid phase Na-dependent depolarization. Furthermore, after the initial increase in cardiac conduction velocity, there will be a prolongation of phase 4 diastolic depolarization and a shortening of the action potential, which leads to a delay in the conduction in the atrioventricular node and His-Purkinje system. On ECG, it manifests as a peaked "tented" T wave. The QRS complex will widen as the condition worsens, resulting in the so-called ''sine wave''. Therefore, hyperkalemia can lead to increased cardiac excitability or decreased cardiac excitability. Increased cardiac excitation can lead to ventricular tachycardia and ventricular fibrillation, while a decrease in cardiac depression leads to various degrees of heart block and asystole.<xref ref-type="bibr" rid="article-31506.r40">[40]</xref> Hyperkalemia can also cause an absence of the P wave on ECG.<xref ref-type="bibr" rid="article-31506.r41">[41]</xref><xref ref-type="bibr" rid="article-31506.r42">[42]</xref> Moreover, patients with hyperkalemia may present with fatigue, dizziness, and weakness.<xref ref-type="bibr" rid="article-31506.r42">[42]</xref></p>
        <p>The initial step in managing amiloride toxicity is to stop all drugs that increase potassium concentrations (including amiloride). The next step is to treat hyperkalemia with 10 mL of 10% calcium gluconate IV over 5 minutes. Because the effect is temporary, another dose might be necessary after 15 minutes. Treating hyperkalemia includes administering rapid-acting insulin, glucose, potassium-binding resins, salbutamol, and sodium bicarbonate.<xref ref-type="bibr" rid="article-31506.r41">[41]</xref> Normal saline should be administered for volume replacement; hypotensive refractory to volume replacement may require dopamine and norepinephrine.<xref ref-type="bibr" rid="article-31506.r43">[43]</xref></p>
      </sec>
      <sec id="article-31506.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Healthcare professionals prescribing amiloride should know its indications, dosage, contraindications, and adverse effects. Monitoring serum potassium and renal function is integral to managing heart failure and hypertension when receiving amiloride. In addition, managing hypertension usually involves prescribing angiotensin-converting enzyme (ACE) inhibitors. Nevertheless, concomitant use of amiloride and ACE inhibitors carries a significant risk of developing symptomatic hyperkalemia.</p>
        <p>When a clinician initiates amiloride therapy, they should collaborate with other&#x000a0;healthcare team members to enhance care coordination and communication.&#x000a0;A cardiologist&#x000a0;should be&#x000a0;consulted for the use of amiloride in settings of resistant hypertension and heart failure. Coordinating with the pathologist for necessary laboratory investigations pertinent to amiloride monitoring (eg, potassium and serum creatinine) is prudent. The pharmacist should also perform a medication reconciliation check for drug interactions and verify dosing. A case-control study explored hyperkalemia prevention strategies in patients with heart failure. It was demonstrated that pharmacist-based multidimensional interventions, as part of an interprofessional healthcare team,&#x000a0;are linked to reduced odds of hyperkalemia.<xref ref-type="bibr" rid="article-31506.r44">[44]</xref> Nursing staff should also have involvement, including patient counseling, monitoring medication adherence, and being aware and alert to signs of adverse events and toxicity. It is necessary to have a collaborative interprofessional team that includes clinicians, specialty-trained nurses, specialists, and pharmacists to&#x000a0;optimize treatment outcomes related to amiloride and minimize adverse drug reactions.</p>
      </sec>
      <sec id="article-31506.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31506&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31506">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31506/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31506">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31506.s11">
        <title>References</title>
        <ref id="article-31506.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vesell</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Beyer</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus.</article-title>
            <source>Toxicology</source>
            <year>2000</year>
            <month>Apr</month>
            <day>03</day>
            <volume>144</volume>
            <issue>1-3</issue>
            <fpage>5</fpage>
            <page-range>5-11</page-range>
            <pub-id pub-id-type="pmid">10781866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vidt</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic.</article-title>
            <source>Pharmacotherapy</source>
            <year>1981</year>
            <season>Nov-Dec</season>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>179</fpage>
            <page-range>179-87</page-range>
            <pub-id pub-id-type="pmid">6927605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Amiloride: A review.</article-title>
            <source>J Renin Angiotensin Aldosterone Syst</source>
            <year>2020</year>
            <season>Oct-Dec</season>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>1470320320975893</fpage>
            <pub-id pub-id-type="pmid">33234024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sethy</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Doshi</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sheth</surname>
                <given-names>UK</given-names>
              </name>
            </person-group>
            <article-title>The potassium-sparing effect of amiloride hydrochloride (MK-870) on the kaliuretic effect of ethacrynic acid.</article-title>
            <source>J Clin Pharmacol J New Drugs</source>
            <year>1968</year>
            <season>Sep-Oct</season>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>309</fpage>
            <page-range>309-14</page-range>
            <pub-id pub-id-type="pmid">5244660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biggins</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Angeli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Garcia-Tsao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gin&#x000e8;s</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Nadim</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.</article-title>
            <source>Hepatology</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>74</volume>
            <issue>2</issue>
            <fpage>1014</fpage>
            <page-range>1014-1048</page-range>
            <pub-id pub-id-type="pmid">33942342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <collab>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group</collab>
            <article-title>KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.</article-title>
            <source>Kidney Int</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>100</volume>
            <issue>4S</issue>
            <fpage>S1</fpage>
            <page-range>S1-S276</page-range>
            <pub-id pub-id-type="pmid">34556256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viswanathan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Subramani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parthasarathy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Subramaniyam</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manoharan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sundaramoorthy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gnudi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Karalliedde</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Viberti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-32</page-range>
            <pub-id pub-id-type="pmid">23184569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pattanayak</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Rajhans</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shakya</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gautam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khandelwal</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Lithium-induced polyuria and amiloride: Key issues and considerations.</article-title>
            <source>Indian J Psychiatry</source>
            <year>2017</year>
            <season>Jul-Sep</season>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>391</fpage>
            <page-range>391-392</page-range>
            <pub-id pub-id-type="pmid">29085107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomkiewicz</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>App</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Zayas</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boucher</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Knowles</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum.</article-title>
            <source>Am Rev Respir Dis</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>148</volume>
            <issue>4 Pt 1</issue>
            <fpage>1002</fpage>
            <page-range>1002-7</page-range>
            <pub-id pub-id-type="pmid">8214916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akkerman-Nijland</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rottier</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Holstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>RLJ</given-names>
              </name>
              <name>
                <surname>Touw</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Akkerman</surname>
                <given-names>OW</given-names>
              </name>
              <name>
                <surname>Koppelman</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Eradication of <italic>Burkholderia cepacia</italic> complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole.</article-title>
            <source>ERJ Open Res</source>
            <year>2023</year>
            <month>May</month>
            <volume>9</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">37377654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oguejiofor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jaar</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Successful Management of Refractory Type 1 Renal Tubular Acidosis with Amiloride.</article-title>
            <source>Case Rep Nephrol</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>8596169</fpage>
            <pub-id pub-id-type="pmid">28127482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rojas</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Corchete</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>San-Segundo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Blanch</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Codo&#x000f1;er</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Pa&#x000ed;no</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Puig</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Sanz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mateos</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Ocio</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Misiewicz-Krzeminska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.</article-title>
            <source>Clin Cancer Res</source>
            <year>2017</year>
            <month>Nov</month>
            <day>01</day>
            <volume>23</volume>
            <issue>21</issue>
            <fpage>6602</fpage>
            <page-range>6602-6615</page-range>
            <pub-id pub-id-type="pmid">28790111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Monticone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burrello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matarazzo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Veglio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pasini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jeunemaitre</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Mulatero</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Liddle Syndrome: Review of the Literature and Description of a New Case.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Mar</month>
            <day>11</day>
            <volume>19</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">29534496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashlan</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Sheng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kleyman</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>On the interaction between amiloride and its putative alpha-subunit epithelial Na+ channel binding site.</article-title>
            <source>J Biol Chem</source>
            <year>2005</year>
            <month>Jul</month>
            <day>15</day>
            <volume>280</volume>
            <issue>28</issue>
            <fpage>26206</fpage>
            <page-range>26206-15</page-range>
            <pub-id pub-id-type="pmid">15908426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aziz</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Memon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Liddle's Syndrome.</article-title>
            <source>J Ayub Med Coll Abbottabad</source>
            <year>2016</year>
            <season>Oct-Dec</season>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>809</fpage>
            <page-range>809-811</page-range>
            <pub-id pub-id-type="pmid">28586600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kleyman</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Cragoe</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>The mechanism of action of amiloride.</article-title>
            <source>Semin Nephrol</source>
            <year>1988</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>242</fpage>
            <page-range>242-8</page-range>
            <pub-id pub-id-type="pmid">2849182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>SU</given-names>
              </name>
              <name>
                <surname>Anjum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Littler</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Use of diuretics in cardiovascular diseases: (1) heart failure.</article-title>
            <source>Postgrad Med J</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>80</volume>
            <issue>942</issue>
            <fpage>201</fpage>
            <page-range>201-5</page-range>
            <pub-id pub-id-type="pmid">15082840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Epstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calhoun</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>644</fpage>
            <page-range>644-8</page-range>
            <pub-id pub-id-type="pmid">21896143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matthesen</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vase</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lauridsen</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial.</article-title>
            <source>Clin Exp Hypertens</source>
            <year>2013</year>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>313</fpage>
            <page-range>313-24</page-range>
            <pub-id pub-id-type="pmid">22966789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Kinetics and bioavailability of two formulations of amiloride in man.</article-title>
            <source>Br J Pharmacol</source>
            <year>1973</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>646</fpage>
            <page-range>646-9</page-range>
            <pub-id pub-id-type="pmid">4788208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uribe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Alb&#x000f3;niga</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Analysis of the Heterogeneous Distribution of Amiloride and Propranolol in Dried Blood Spot by UHPLC-FLD and MALDI-IMS.</article-title>
            <source>Molecules</source>
            <year>2019</year>
            <month>Nov</month>
            <day>26</day>
            <volume>24</volume>
            <issue>23</issue>
            <pub-id pub-id-type="pmid">31779239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morant</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Caulfield</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cruickshank</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salsbury</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mackenzie</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Padmanabhan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>TM</given-names>
              </name>
              <collab>British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group</collab>
            </person-group>
            <article-title>Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-47</page-range>
            <pub-id pub-id-type="pmid">26489809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krysiak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Samborek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stojko</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Primary aldosteronism in pregnancy.</article-title>
            <source>Acta Clin Belg</source>
            <year>2012</year>
            <season>Mar-Apr</season>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>130</fpage>
            <page-range>130-4</page-range>
            <pub-id pub-id-type="pmid">22712170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>e26</fpage>
            <page-range>e26-e50</page-range>
            <pub-id pub-id-type="pmid">30575676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r26">
          <label>26</label>
          <element-citation publication-type="book">
            <chapter-title>Amiloride</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>8</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">30000009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lande</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Treatment of hypertension in children and adolescents.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>10</issue>
            <fpage>1939</fpage>
            <page-range>1939-49</page-range>
            <pub-id pub-id-type="pmid">17690916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaz de Castro</surname>
                <given-names>PAS</given-names>
              </name>
              <name>
                <surname>Bitencourt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Oliveira Campos</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Soares de Brito</surname>
                <given-names>SBC</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Sim&#x000f5;es E Silva</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic diabetes insipidus: a comprehensive overview.</article-title>
            <source>J Pediatr Endocrinol Metab</source>
            <year>2022</year>
            <month>Apr</month>
            <day>26</day>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>421</fpage>
            <page-range>421-434</page-range>
            <pub-id pub-id-type="pmid">35146976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arai</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Medical management of congestive heart failure.</article-title>
            <source>West J Med</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>153</volume>
            <issue>4</issue>
            <fpage>406</fpage>
            <page-range>406-14</page-range>
            <pub-id pub-id-type="pmid">2244376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villa-Zapata</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carhart</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hansten</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Subbian</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gephart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malone</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2021</year>
            <month>Dec</month>
            <day>09</day>
            <volume>78</volume>
            <issue>24</issue>
            <fpage>2245</fpage>
            <page-range>2245-2255</page-range>
            <pub-id pub-id-type="pmid">34013341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yusuff</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Okoh</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <article-title>Frequency, types and factors associated with potentially harmful drug interactions in ambulatory elderly patients in Nigeria.</article-title>
            <source>Int J Pharm Pract</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>353</fpage>
            <page-range>353-6</page-range>
            <pub-id pub-id-type="pmid">25474395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lehnhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kemper</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis, diagnosis and management of hyperkalemia.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>377</fpage>
            <page-range>377-84</page-range>
            <pub-id pub-id-type="pmid">21181208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berkova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berka</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Topinkova</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Arrhythmias and ECG changes in life threatening hyperkalemia in older patients treated by potassium sparing drugs.</article-title>
            <source>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</source>
            <year>2014</year>
            <volume>158</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-91</page-range>
            <pub-id pub-id-type="pmid">23128820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spahn</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mutschler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gerok</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Knauf</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of amiloride in renal and hepatic disease.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1987</year>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>493</fpage>
            <page-range>493-8</page-range>
            <pub-id pub-id-type="pmid">3428342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Svendsen</surname>
                <given-names>UG</given-names>
              </name>
              <name>
                <surname>Ibsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Dige-Petersen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Giese</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effects of combined therapy with amiloride and hydrochlorothiazide on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in hypertensive patients.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1986</year>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>151</fpage>
            <page-range>151-6</page-range>
            <pub-id pub-id-type="pmid">3519243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Bistrup</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Henriksen</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.</article-title>
            <source>J Hypertens</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>1621</fpage>
            <page-range>1621-9</page-range>
            <pub-id pub-id-type="pmid">27214087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wan</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lye</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Moduretic-induced metabolic acidosis and hyperkalaemia.</article-title>
            <source>Postgrad Med J</source>
            <year>1980</year>
            <month>May</month>
            <volume>56</volume>
            <issue>655</issue>
            <fpage>348</fpage>
            <page-range>348-50</page-range>
            <pub-id pub-id-type="pmid">7443596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montford</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Linas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>How Dangerous Is Hyperkalemia?</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>11</issue>
            <fpage>3155</fpage>
            <page-range>3155-3165</page-range>
            <pub-id pub-id-type="pmid">28778861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kokot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hyla-Klekot</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced abnormalities of potassium metabolism.</article-title>
            <source>Pol Arch Med Wewn</source>
            <year>2008</year>
            <season>Jul-Aug</season>
            <volume>118</volume>
            <issue>7-8</issue>
            <fpage>431</fpage>
            <page-range>431-4</page-range>
            <pub-id pub-id-type="pmid">18714739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belkouch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Belyamani</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>An unusual manifestation of hyperkalemia.</article-title>
            <source>Pan Afr Med J</source>
            <year>2014</year>
            <volume>19</volume>
            <fpage>251</fpage>
            <pub-id pub-id-type="pmid">25852794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foulon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The hemodynamic effects of norepinephrine: far more than an increase in blood pressure!</article-title>
            <source>Ann Transl Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>Suppl 1</issue>
            <fpage>S25</fpage>
            <pub-id pub-id-type="pmid">30613600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31506.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallo-Bernal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Calixto</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Molano-Gonz&#x000e1;lez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>MPD</given-names>
              </name>
              <name>
                <surname>Tamayo</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Contreras</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Medina</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Impact of a pharmacist-based multidimensional intervention aimed at decreasing the risk of hyperkalemia in heart failure patients: A Latin-American experience.</article-title>
            <source>Int J Cardiol</source>
            <year>2021</year>
            <month>Apr</month>
            <day>15</day>
            <volume>329</volume>
            <fpage>136</fpage>
            <page-range>136-143</page-range>
            <pub-id pub-id-type="pmid">33412183</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
